Primary mediastinal B-cell lymphoma: a nationwide real-life retrospective study of first-line treatment approaches in Italy.
Not available.
We have 2 of 10 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Not available.
T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these ch...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.